2020 in Scientists’ Own Words
2020 in Scientists’ Own Words
The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.
2020 in Scientists’ Own Words
2020 in Scientists’ Own Words

The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.

The world was rocked by the COVID-19 pandemic this year, but researchers rose to all manner of challenges.

antibodies
T Cells: A New Hope for Lasting Protection against SARS-CoV-2
T Cells: A New Hope for Lasting Protection against SARS-CoV-2
The Scientist Creative Services Team | Dec 15, 2020
Alessandro Sette and Shane Crotty discuss the T cell response to SARS-CoV-2 and the implications for vaccine design and robust immune memory.
Study Estimates 76 Percent of Brazilian City Exposed to SARS-CoV-2
Study Estimates 76 Percent of Brazilian City Exposed to SARS-CoV-2
Ignacio Amigo | Dec 14, 2020
The number, extrapolated from antibodies present in blood donors in Manaus, should be treated with caution, experts warn.
A Greener Recombinant Monoclonal Antibody
A Greener Recombinant Monoclonal Antibody
The Scientist Creative Services Team | Dec 9, 2020
Learn more about environmentally-friendly antibodies that deliver superior performance.
Blocking Cancer Progression and Shrinking Tumors with Antibody-ligand Traps
Blocking Cancer Progression and Shrinking Tumors with Antibody-ligand Traps
The Scientist Creative Services Team | Dec 4, 2020
LuZhe Sun will discuss TGFβ signaling during cancer progression and how researchers can target this pathway.
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Immunity to SARS-CoV-2 Lasts at Least Six Months, Data Show
Ashley Yeager | Nov 23, 2020
Half a year after infection, people who had recovered from COVID-19 had robust antibodies, along with traces of the virus in their gut, which may drive long-lasting immunity.
Common Cold Coronaviruses Tied to Less Severe COVID-19 Cases
Common Cold Coronaviruses Tied to Less Severe COVID-19 Cases
Anthony King | Nov 11, 2020
Outcomes in COVID-19 patients may be better in those recently infected with endemic coronaviruses. 
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Ashley Yeager | Oct 27, 2020
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
More SARS-CoV-2 Reinfections Reported, But Still a Rare Event
More SARS-CoV-2 Reinfections Reported, But Still a Rare Event
Ashley Yeager | Oct 26, 2020
Repeat COVID-19 cases could offer clues about people’s immunity to the novel coronavirus and how to vaccinate against it.
Rapid Characterization of the SARS-CoV-2 Immune Response Using the Simple Western Multi-Antigen Serology Assay
Rapid Characterization of the SARS-CoV-2 Immune Response Using the Simple Western Multi-Antigen Serology Assay
The Scientist Creative Services Team | Oct 21, 2020
The Simple Western automated western blotting platform accelerates characterization of the human IgG immune response to COVID-19.